NO20073723L - Ibandronatpolymorf A - Google Patents

Ibandronatpolymorf A

Info

Publication number
NO20073723L
NO20073723L NO20073723A NO20073723A NO20073723L NO 20073723 L NO20073723 L NO 20073723L NO 20073723 A NO20073723 A NO 20073723A NO 20073723 A NO20073723 A NO 20073723A NO 20073723 L NO20073723 L NO 20073723L
Authority
NO
Norway
Prior art keywords
ibandronate
ibandronate polymorph
polymorph
hydroxypropane
pentyl
Prior art date
Application number
NO20073723A
Other languages
English (en)
Norwegian (no)
Inventor
Uwe Eiermann
Bernd Junghans
Bernhard Knipp
Tim Sattelkau
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36090730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073723(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20073723L publication Critical patent/NO20073723L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073723A 2005-02-01 2007-07-18 Ibandronatpolymorf A NO20073723L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05100686 2005-02-01
PCT/EP2006/000580 WO2006081963A1 (fr) 2005-02-01 2006-01-24 Forme polymorphe a de l'ibandronate

Publications (1)

Publication Number Publication Date
NO20073723L true NO20073723L (no) 2007-08-28

Family

ID=36090730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073723A NO20073723L (no) 2005-02-01 2007-07-18 Ibandronatpolymorf A

Country Status (25)

Country Link
US (1) US7714158B2 (fr)
EP (2) EP1848728B1 (fr)
JP (2) JP5828608B2 (fr)
KR (1) KR100908529B1 (fr)
CN (1) CN101111504B (fr)
AR (1) AR053012A1 (fr)
AU (1) AU2006210009B2 (fr)
BR (1) BRPI0607092A2 (fr)
CA (1) CA2594802C (fr)
CY (1) CY1121703T1 (fr)
DK (1) DK2662380T3 (fr)
ES (2) ES2712644T3 (fr)
HU (1) HUE042316T2 (fr)
IL (1) IL184562A (fr)
LT (1) LT2662380T (fr)
MX (1) MX2007009107A (fr)
NO (1) NO20073723L (fr)
PL (1) PL2662380T3 (fr)
PT (1) PT2662380T (fr)
RU (1) RU2368617C2 (fr)
SI (1) SI2662380T1 (fr)
TR (1) TR201902609T4 (fr)
TW (1) TWI374889B (fr)
WO (1) WO2006081963A1 (fr)
ZA (1) ZA200706168B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930011B1 (fr) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Forme cristalline de ibandronate de sodium
PL1848727T3 (pl) * 2005-02-01 2015-11-30 Hoffmann La Roche Polimorf b ibandronianu
WO2007074475A2 (fr) * 2005-12-27 2007-07-05 Natco Pharma Limited Nouvelles formes polymorphes de l'ibandronate
AU2007270897A1 (en) * 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
TW200829256A (en) * 2006-11-16 2008-07-16 Teva Pharma Crystalline forms of ibandronate sodium
CA2570949A1 (fr) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Solvate d'ibandronate sodique et de propyleneglycol et methodes de preparation connexes
US7662990B2 (en) * 2007-04-11 2010-02-16 Hoffmann-La Roche Inc. Process for preparing ibandronate
EP2316841A1 (fr) 2007-04-19 2011-05-04 Dr. Reddy's Laboratories Limited Formes polymorphes de l'ibandronate sodium
US20090042839A1 (en) * 2007-08-09 2009-02-12 Sharon Avhar-Maydan Crystalline forms of ibandronate sodium
EP2128166A1 (fr) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Formes polymorphes d'ibandronate de sodium et leur procédé de préparation
EP2180003A1 (fr) 2008-10-21 2010-04-28 Zentiva, k.s. Préparation de l'ibandronate de trisodium
WO2012007021A1 (fr) 2010-07-14 2012-01-19 Pharmathen S.A. Procédé de synthèse du sel d'acide 3-(n-méthyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonique ou de ses dérivés
TR201200588A2 (tr) 2012-01-18 2012-07-23 Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
KR20200085441A (ko) 2019-01-07 2020-07-15 엠에프씨 주식회사 이반드로네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
TW198039B (fr) * 1988-11-28 1993-01-11 Ciba Geigy Ag
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (fr) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
PT1121375E (pt) 1998-10-16 2003-07-31 Akzo Nobel Nv Composto de elevada pureza de (7alfa, 17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona
BR9915927A (pt) 1998-12-04 2001-08-21 Roche Diagnostics Gmbh Uso de ácido ibandrÈnico ou seus sais ou ésteres fisiologicamente compatìveis
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CN1404836A (zh) * 2001-09-14 2003-03-26 中生北方生物工程开发研究所 埃本膦酸钠作为预防和治疗骨质疏松症的药物的有效成分的应用
JP2005522526A (ja) 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
EP1790347B1 (fr) 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG Comprimé comprenant une dose haute d'ibandronate
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP1930011B1 (fr) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Forme cristalline de ibandronate de sodium

Also Published As

Publication number Publication date
EP1848728A1 (fr) 2007-10-31
RU2368617C2 (ru) 2009-09-27
SI2662380T1 (sl) 2019-04-30
CA2594802C (fr) 2012-11-27
EP1848728B1 (fr) 2014-06-11
HUE042316T2 (hu) 2019-06-28
TWI374889B (en) 2012-10-21
JP2008529980A (ja) 2008-08-07
JP2015205907A (ja) 2015-11-19
LT2662380T (lt) 2019-03-12
CN101111504A (zh) 2008-01-23
PT2662380T (pt) 2019-02-27
CN101111504B (zh) 2011-12-21
WO2006081963A1 (fr) 2006-08-10
MX2007009107A (es) 2007-09-11
IL184562A (en) 2015-11-30
EP2662380B1 (fr) 2018-11-21
AR053012A1 (es) 2007-04-18
CY1121703T1 (el) 2020-07-31
RU2007132701A (ru) 2009-03-10
AU2006210009B2 (en) 2009-08-13
US7714158B2 (en) 2010-05-11
EP2662380A1 (fr) 2013-11-13
ES2478302T3 (es) 2014-07-21
KR100908529B1 (ko) 2009-07-20
ES2712644T3 (es) 2019-05-14
TW200638939A (en) 2006-11-16
CA2594802A1 (fr) 2006-08-10
PL2662380T3 (pl) 2019-05-31
DK2662380T3 (en) 2019-03-18
KR20070100394A (ko) 2007-10-10
US20060172975A1 (en) 2006-08-03
BRPI0607092A2 (pt) 2009-08-04
TR201902609T4 (tr) 2019-03-21
JP6039754B2 (ja) 2016-12-07
JP5828608B2 (ja) 2015-12-09
IL184562A0 (en) 2007-10-31
ZA200706168B (en) 2008-09-25
AU2006210009A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
NO20073723L (no) Ibandronatpolymorf A
NO20073755L (no) Ibandronatpolymorf B
IL182690A0 (en) Process for the preparation of ibandronate
IL172513A0 (en) Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
NO20076597L (no) Fremgangsmater for fremstilling av 4-(bifenylyl)azetidin-2-one fosforsyrer
NO20084783L (no) Syntese av acylaminoalkenylenamider nyttige som substans P antagonister
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
CA2565660A1 (fr) Composes aryl- ou heteroarylamides ortho-substitues
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
WO2007074475A3 (fr) Nouvelles formes polymorphes de l'ibandronate
MY159913A (en) Dihydroetorphines and their preparation
NO20076161L (no) Fremgangsmater for fremstilling av 4-bifenylazetidin-2-oner
ZA200800138B (en) Process for the preparation of crystalline perindopril
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
MX2009010850A (es) Sintesis de ibandronato en multiples etapas.
NO20091971L (no) Saltformer av substituerte benzotienylforbindelser
TH84983A (fr)
EA200501691A1 (ru) Новый промежуточный продукт для получения терапевтически активных имидазопиридинов
TH96053A (th) เกลือไฮโดรเจนซัลเฟตชนิดใหม่
WO2010084507A3 (fr) Procédé de synthèse du n-méthyl-2-[3-(1-méthyl-4-pipéridyl)-1h-indol-5-yl]-éthanesulfonamide et de ses sels d'addition acide
TH85269B (th) อิแบนโดรเนตพอลิมอร์ฟ a
TH96053B (th) เกลือไฮโดรเจนซัลเฟตชนิดใหม่
TH84983B (th) พหุสัณฐานไดแบนโดรเนท b
TH115418B (th) ไดไฮโดรเอเทอร์ฟีนและการเตรียมไดไฮโดรเอทอร์ฟีนเหล่านี้

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ATNAHS PHARMA UK LIMITED, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application